c-RET
Gli inibitori di c-RET prendono di mira il proto-oncogene RET (Rearranged during Transfection), che codifica una tirosina chinasi recettoriale coinvolta nella crescita, differenziazione e sopravvivenza cellulare. L'attivazione anomala della segnalazione RET può portare a una proliferazione cellulare incontrollata e alla resistenza all'apoptosi, contribuendo allo sviluppo di tumori come il carcinoma midollare della tiroide e il carcinoma polmonare non a piccole cellule. L'inibizione di c-RET può indurre l'apoptosi nelle cellule tumorali ed è un approccio promettente nella terapia oncologica mirata. Presso CymitQuimica, offriamo una varietà di inibitori di c-RET di alta qualità per supportare la tua ricerca in oncologia, trasduzione del segnale e apoptosi.
Trovati 64 prodotti per "c-RET".
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TG-89
CAS:TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian andFormula:C26H34N6O3SPurezza:98.68%Colore e forma:White SolidPeso molecolare:510.65Pz-1
CAS:Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.Formula:C26H26N6O2Purezza:99.89%Colore e forma:White SolidPeso molecolare:454.52RET-IN-23
CAS:RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.Formula:C28H28FN11Purezza:97.46%Colore e forma:SolidPeso molecolare:537.59Ref: TM-T79099
10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta1mg264,00€5mg650,00€RET-IN-3
CAS:RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.Formula:C18H21N5O2Purezza:99.83%Colore e forma:SolidPeso molecolare:339.39RET-IN-17
CAS:RET-IN-17 inhibits RET kinase; may help in IBS pain and RET-activated cancers.Formula:C27H28F4N4O4Colore e forma:SolidPeso molecolare:548.53RET-IN-25
CAS:RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximalFormula:C22H17N3O5SColore e forma:SolidPeso molecolare:435.45FHND5071
CAS:FHND5071, a potent and selective RET kinase inhibitor, exerts antitumor effects through the inhibition of RET autophosphorylation and may be utilized for tumorFormula:C30H30D3N9OColore e forma:SolidPeso molecolare:538.66NSC194598
CAS:NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM.Formula:C20H19N3OColore e forma:SolidPeso molecolare:317.38FLT3/ITD-IN-4
CAS:FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).Formula:C25H22N4O5Colore e forma:SolidPeso molecolare:458.47RET-IN-24
CAS:RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].Formula:C27H26F2N8OColore e forma:SolidPeso molecolare:516.55RET-IN-5
CAS:RET-IN-5 is a potent inhibitor of RET (IC50: 4.57 nM).Formula:C29H26FN9OColore e forma:SolidPeso molecolare:535.57RET-IN-13
CAS:RET-IN-13: potent quinoline RET inhibitor; IC50 = 0.5 nM (WT), 0.9 nM (V804M); potential for RET-related tumor/intestinal disease research.Formula:C32H33F4N5O3Colore e forma:SolidPeso molecolare:611.63RET-IN-10
CAS:RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).Formula:C29H28N8OSColore e forma:SolidPeso molecolare:536.65WF-47-JS03
WF-47-JS03: RET kinase inhibitor, crosses blood-brain barrier, 500x more selective for KDR, IC50: 1.7 nM in Ba/F3 cells, 5.3 nM in LC-2/ad lung cancer cells.Formula:C30H38N6O2Colore e forma:SolidPeso molecolare:514.66FHND5071 (1H)
CAS:FHND5071 (1H) is a selective inhibitor of RET (rearranged during transfection) tyrosine kinase. It shows potential for research applications in RET-driven cancers, such as thyroid and lung cancer.Formula:C30H33N9OColore e forma:SolidPeso molecolare:535.64LRRK2-IN-17
CAS:LRRK2-IN-17 is an orally active LRRK2 inhibitor with IC50 values of 3.5 nM for WT and 3.3 nM for G2019S, and it also inhibits RET kinase with an IC50 of 59 nM. LRRK2-IN-17 is utilized in research related to cancer and Parkinson's disease (PD).Formula:C18H18N8Colore e forma:SolidPeso molecolare:346.39TAS05567
CAS:TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).Formula:C21H29N9O2Purezza:98%Colore e forma:SolidPeso molecolare:439.51RET-IN-30
CAS:RET-IN-30 (Compound 28) is a RET inhibitor that exhibits inhibitory activity against both wild-type RET and some of its mutants. It is capable of inhibiting the proliferation of A549 cells and demonstrates antitumor properties.Formula:C26H26FN5OColore e forma:SolidPeso molecolare:443.52RET-IN-9
CAS:RET-IN-9 is a potent RET kinase inhibitor, potentially useful for studying RET-related diseases, including lung and thyroid cancer.Formula:C26H27N9OColore e forma:SolidPeso molecolare:481.55RET-IN-7
CAS:RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice throughFormula:C22H24ClFN6O2Colore e forma:SolidPeso molecolare:458.92
